Charles Wilson

Biography

huck leads the company. Before founding Unum, Chuck led partnering for Novartis research, and was responsible for all efforts in drug discovery up through Phase II clinical development. He brings deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies. Prior to Novartis, Chuck held both scientific and business management roles in biotechnology. Chuck received his PhD from the University of California, San Francisco, and completed his post-doctoral training at Harvard University / Massachusetts General Hospital. 

Research Interest

Unum is a Cambridge, MA-based company developing cellular immunotherapies based on an antibody-coupled T-cell receptor, or ACTR (pronounced ‘actor’). When combined with an antibody that recognizes a target on the surface of tumor cells, the ACTR receptor can direct an individual’s T-cells to kill the tumor. Unlike other approaches (such as CAR-T or TCR), in which a cell’s receptor is trained to treat a narrow set of tumors, our therapy is not restricted to a particular target and may be used in many different cancer types.